Abstract Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is a molecular and functional imaging modality with better restaging accuracy over conventional imaging for detecting prostate cancer in men suspected of lymph node (LN) progression after definitive therapy. However, the availability of PSMA PET/CT is limited in both low-resource settings and for repeating imaging surveillance. In contrast, CT is widely available, cost-effective, and routinely performed as part of patient follow-up or radiotherapy workflow. Compared with the molecular activities, the morphological and texture changes of subclinical LNs in CT are subtle, making manual detection of positive LNs infeasible. Instead, w...
Here, we aimed to develop and validate a fully automated artificial intelligence (AI)-based method f...
Purpose:PET/CT with the PSMA ligand is a powerful new method for the early detection of nodal metast...
Our objective was to determine the diagnostic capabilities of combined prostate-specific membrane an...
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT...
Purpose In recurrent prostate carcinoma, determination of the site of recurrence is crucial to guide...
The emerging PSMA-targeted radionuclide therapy provides an effective method for the treatment of ad...
Purpose: The aim of this study was to develop and validate an artificial intelligence (AI)-based met...
BACKGROUND: Many patients experience recurrence of prostate cancer after radical prostatectomy. OBJE...
Introduction: Lymph node metastases are a key prognostic factor in prostate cancer (PCa), but detect...
Here, we aimed to develop and validate a fully automated artificial intelligence (AI)-based method f...
68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a new method to detect early nodal metastas...
PURPOSE: This study proposes an automated prostate cancer (PC) lesion characterization method base...
BACKGROUND: Approximately 20-40% of patients with prostate cancer (PC) who undergo radical prostatec...
Purpose: The emerging PSMA targeted radionuclide therapy provides an effective method for the treat...
Prostate-specific membrane antigen [4_TD$DIFF]Positron-emission tomography Prostate cancer Prostate-...
Here, we aimed to develop and validate a fully automated artificial intelligence (AI)-based method f...
Purpose:PET/CT with the PSMA ligand is a powerful new method for the early detection of nodal metast...
Our objective was to determine the diagnostic capabilities of combined prostate-specific membrane an...
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT...
Purpose In recurrent prostate carcinoma, determination of the site of recurrence is crucial to guide...
The emerging PSMA-targeted radionuclide therapy provides an effective method for the treatment of ad...
Purpose: The aim of this study was to develop and validate an artificial intelligence (AI)-based met...
BACKGROUND: Many patients experience recurrence of prostate cancer after radical prostatectomy. OBJE...
Introduction: Lymph node metastases are a key prognostic factor in prostate cancer (PCa), but detect...
Here, we aimed to develop and validate a fully automated artificial intelligence (AI)-based method f...
68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a new method to detect early nodal metastas...
PURPOSE: This study proposes an automated prostate cancer (PC) lesion characterization method base...
BACKGROUND: Approximately 20-40% of patients with prostate cancer (PC) who undergo radical prostatec...
Purpose: The emerging PSMA targeted radionuclide therapy provides an effective method for the treat...
Prostate-specific membrane antigen [4_TD$DIFF]Positron-emission tomography Prostate cancer Prostate-...
Here, we aimed to develop and validate a fully automated artificial intelligence (AI)-based method f...
Purpose:PET/CT with the PSMA ligand is a powerful new method for the early detection of nodal metast...
Our objective was to determine the diagnostic capabilities of combined prostate-specific membrane an...